Some of the major updates include the approval of acalabrutinib (Calquence) for first-line treatment of mantle cell lymphoma, the FDA’s priority review of fam-trastuzumab deruxtecan-nxki (T-DXd; ...
Over the summer, the researchers published a new study in the journal Nutrients showing that Manuka honey could have the ...
On the left, ecDNAs that link together to enhance cancer cell growth tend to be inherited together by daughter cells after ...
The procedure, called Uterine Transposition, consists on temporarily suspending the uterus in the abdomen so the patient can receive radiation without affecting it ...
Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®â–¼ (erdafitinib) as a monotherapy for the treatment ...
A Michigan State University researcher's new model for studying breast cancer could help scientists better understand why and ...
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces new positive survival data, ...
A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...
While it remains unclear why AstraZeneca China President Leon Wang has been detained, news of his arrest comes just days ...
Virologist Beata Halassy says self-treatment worked and was a positive experience — but researchers warn that it is not ...
ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.
Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback